HCPCS Level II · Medical services and quality measures
M1412Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About M1412
M1412 is an HCPCS Level II code in the M series (medical services and quality measures), describing patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement.
It was added to HCPCS effective 01/01/2025.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Met nsclc w/ egfr alk oth ab
- Date added
- 01/01/2025
- Action effective
- 01/01/2025
- BETOS
- Z2
Related M14xx codes
- M1400Patients who died during the follow-up period
- M1401Stages i-iii breast cancer
- M1402Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group
- M1403Patients with baseline and follow-up promis surveys documented in the medical record
- M1404Patients on a therapeutic clinical trial
- M1405Patients with recurrence/disease progression
- M1406Patients who leave the practice during the follow-up period
- M1407Patients who died during the follow-up period
- M1408Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
- M1409Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1410Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1411Currently on first-line immune checkpoint inhibitors without chemotherapy
Common questions about M1412
Is HCPCS M1412 still valid?
- Yes. M1412 is active in the CMS October 2026 HCPCS file.
Does Medicare cover M1412?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.